Corcept Therapeutics Incorporated (CORT) Stock Forecast
CORT analyst forecast
as of October 18, 2026- Analyst consensus
- Buy 4.00 / 5 from 5 analysts
- Price target
- $141.00 average of analyst targets
- Upside to target
- +28.0% from the latest close
- Next earnings
- November 3, 2026 EPS estimate $0.68
- 52-week range
- $32.15 – $123.57
CORT analyst ratings
5 analystsNumber of analysts at each rating.
CORT price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
CORT earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.84 | $0.74 | $1.03 | $0.16 | +425.0% | 4 |
| Current fiscal year (2026) | $2.12 | $1.84 | $2.41 | $0.82 | +158.5% | 4 |
| Next fiscal year (2027) | $4.41 | $1.85 | $7.69 | $2.12 | +107.8% | 4 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
CORT revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $336.4M | $329.5M | $350.0M | +62.0% | 4 |
| Current fiscal year (2026) | $1.15B | $1.13B | $1.16B | +50.5% | 4 |
| Next fiscal year (2027) | $1.71B | $1.54B | $2.06B | +48.9% | 4 |
CORT EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
CORT revenue: reported and forecast
CORT EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.25 | $0.85 | $0.86 | $0.86 | $0.84 | +231.6% | 1 up · 0 down |
| Current fiscal year (2026) | $0.56 | $2.13 | $2.15 | $2.15 | $2.12 | +280.8% | 1 up · 0 down |
| Next fiscal year (2027) | $3.21 | $4.52 | $4.40 | $4.40 | $4.41 | +37.4% | 2 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
CORT earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; CORT beat in 9 of 12.
What analysts expect from CORT
5 analysts cover Corcept Therapeutics; their consensus rating is buy (4.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $141.00, 28.0% above the latest close of $110.16. Analysts expect earnings of $2.12 per share for 2026, +158.5% from a year earlier. For 2027 the average estimate is $4.41 per share on revenue of $1.7 billion. Corcept Therapeutics beat the EPS estimate in 9 of the last 12 quarters.
Related: CORT income statement, CORT key metrics, CORT chart. See the CORT stock overview for the latest quote and news.
CORT forecast FAQ
What is Corcept Therapeutics's price target?
The average analyst price target for Corcept Therapeutics is $141.00, 28.0% above the latest close of $110.16.
Is Corcept Therapeutics a buy, hold or sell?
Of 5 analysts covering Corcept Therapeutics, 3 rate it a strong buy, 1 a buy, 0 a hold, 0 a sell and 1 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Corcept Therapeutics's EPS forecast?
Analysts forecast $2.12 per share for 2026 (range $1.84 to $2.41); for 2027 the estimate is $4.41.
What is Corcept Therapeutics's revenue forecast?
The average revenue estimate for 2026 is $1.1 billion, growth of 50.5%; for 2027 it is $1.7 billion.
When does Corcept Therapeutics report earnings?
Corcept Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 3, 2026; the EPS estimate is $0.68.
Does Corcept Therapeutics usually beat earnings estimates?
Corcept Therapeutics reported EPS at or above the analyst estimate in 9 of the last 12 quarters.